Growing healthcare awareness among individuals, the rising prevalence of chronic diseases, and drug discoveries are contributing to the pharmaceutical industry’s growth. Moreover, the pharma companies are poised to remain resilient, given the inelastic demand for healthcare products and services.
In this article, I evaluated two pharma stocks, Johnson & Johnson (JNJ) and Curaleaf Holdings, Inc. (CURLF), to determine which could be a better buy in July.
